Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pulmonary Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pulmonary Other
    Protein May Be Strongest Indicator of Idiopathic Pulmonary Fibrosis - (DGNews)
    FDA Approves Tadalafil Tablets for Pulmonary Arterial Hypertension - (DGNews)
    Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis - (JAMA)
    Patients With Pulmonary Arterial Hypertension Treated With Chronic Dosing of Treprostinil Sustain Plasma Concentrations: Presented at ATS - (DGDispatch)
    Early Flexible Bronchoscopy Effective, Safe in Severely Immunocompromised Patients With Febrile Neutropenia: Presented at ATS - (DGDispatch)

    News archive

     Recent webcasts/CME - Pulmonary Other
    • State of the Art in Pulmonary Arterial Hypertension
    • The Pathophysiology and Treatment of Dyspnea
      An Introduction to Pleural Ultrasonography for the Pulmonary and Critical Care Physician
      World Health Organization Groups II and III Pulmonary Hypertension: When and How To Treat
      Tracheobronchial Foreign Body Aspiration in Adults

      Webcasts/CME archive

       Recent cases - Pulmonary Other
        Fatal Pneumonitis After Treatment with Docetaxel and Trastuzumab
        Abnormal Presentation of Pulmonary Langerhans Cell Histiocytosis
        Mounier-Kuhn Syndrome, A Case Report
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > pulmonary other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Radical Decortication/Pleurectomy Best Surgical Approach for N2 Malignant Mesothelioma: Presented at STS

        By Ed Susman

        FORT LAUDERDALE, FL -- February 1, 2008 -- Patients who underwent the more extensive treatment of radical decortication/pleurectomy in attempt to cure stage 3 pure epithelial mesothelioma appear to have significantly better outcomes than patients who had less extensive operations, according to a study presented here at the Society of Thoracic Surgeons 44th Annual Meeting (STS).

        "There is no gold standard surgical procedure in stage 3 mesothelioma," said Delphine Trousse, MD, Registrar in Thoracic Surgery, Hôpital Sainte Marguerite, Marseille, France, in a presentation on January 29.

        However, in reviewing 127 consecutive cases of patients who presented with stage 3 mesothelioma, Dr. Trousse found that the 57 patients who underwent radical decortication/pleurectomy had better overall survival at 1 year (83%) and at 2 years (73%) than did patients treated with alternative surgical techniques.

        One-year survival among the 35 patients treated by extrapleural pneumonectomy was 55% and 2-year survival was 18%. One-year survival for 35 patients who were treated by vascular access thorosectomy (VATS) decortication/pleurectomy was 67% and 2-year survival was 22%.

        The difference between the extensive surgery and the less extensive treatments reached statistical significance at the P =.003 level.

        Dr. Trousse's oral presentation reported used data from Glenfield Hospital, Leicester, England, United Kingdom, where she conducted her research before relocating to Marseille, France.

        "These data support the preferential choice of radical pleurectomy/decortication in surgery for N2 positive epithelial mesothelioma," she said.

        She noted that 90-day survival in the series was best among patients who underwent VATS pleurectomy/decortication (P =.024). VATS surgery was reserved for patients who were either too frail or had comorbidities that made them unfit for the more extensive surgical procedures.

        "Long-term survival was not associated with sex, age," she said. There were 104 men and 23 women in the series; the average age of the patients undergoing surgery was 62 years.

        "Median survival for the whole group was 50 months, with 1-year survival of 63%, 38% at 2 years and 14% at 3 years, which is pretty good survival for stage 3 mesothelioma," Dr. Trousse said.


        [Presentation title: Which is the Best Surgical Approach for N2 Positive Epithelial Malignant Mesothelioma? Long-Term Outcome After Extrapleural Pneumonectomy Versus Radical and VATS Decortication/Pleurectomy. Abstract 42]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send